With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
On Monday, the European Medicines Agency approved GSK's Rotarix (see article in the Financial Times). This comes right on the heels of the U.S. Food and Drug Administration's approval of Merck's rival vaccine Rotateq; both offer children protection against diarrheal disease caused by rotavirus, which kills nearly 500,000 children and hospitalizes two million more.
Like Merck before it, GSK has pledged to make their vaccine available and affordable to developing countries, but has not yet completed the necessary clinical trials.
CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.